SCHEDULE: Avoro Capital Reduces Amicus Therapeutics Stake to 4.87%

Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 4.87% in Amicus Therapeutics, Inc., holding 15,025,000 shares.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh (the "Reporting Persons") have filed an Amendment No. 5 to Schedule 13G regarding their beneficial ownership of Amicus Therapeutics, Inc. (the "Issuer").
• The Reporting Persons collectively beneficially own 15,025,000 shares of Amicus Therapeutics' Common Stock.
• This represents 4.87% of the Issuer's outstanding Common Stock, calculated based on 308,239,374 shares outstanding as of July 25, 2025.
• Avoro Capital Advisors LLC is a Delaware limited liability company providing investment advisory and management services, holding shares for investment purposes on behalf of Avoro Life Sciences Fund LLC.
• Behzad Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a reduction in stake below 5%. While a reduction could be seen negatively, the filing itself is a standard compliance document and does not inherently convey strong positive or negative sentiment about the company's performance or prospects. It simply reports a change in an institutional investor's position.

Future Outlook

NA

Industry Context

This filing indicates a passive investment position by a specialized life sciences fund in a biotechnology company. Such filings are common for institutional investors adjusting their portfolio holdings, reflecting a change in their stake rather than a strategic shift for the issuer.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership changes, which can influence market perception and trading activity.
• Investment Community: Offers insight into the investment decisions of Avoro Capital Advisors, a specialized life sciences fund.

Key Dates

Recommendation

This Schedule 13G filing indicates that Avoro Capital Advisors and Behzad Aghazadeh have reduced their beneficial ownership in Amicus Therapeutics to 4.87%, falling below the 5% threshold. While a reduction in a significant institutional stake could be interpreted negatively, a 13G filing primarily serves as a disclosure of ownership changes and does not provide sufficient fundamental information about the company's operational performance, financial health, or future prospects to warrant a 'buy' or 'sell' recommendation. Investors should consider this information in conjunction with the company's financial reports and other market data. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to alter an existing investment position.

Keywords

Amicus Therapeutics, Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals